Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients (2025) Rautenberg C, Middeke JM, Röllig C, Stelljes M, Gaidzik V, Kriege O, Verbeek M, et al. Journal article Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years (2024) Berning P, Fekom M, Ngoya M, Goldstone AH, Dreger P, Montoto S, Finel H, et al. Journal article Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy (2024) Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TA, Fenk R, et al. Journal article UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome (2023) Georgi JA, Stasik S, Eckardt JN, Zukunft S, Hartwig M, Röllig C, Middeke JM, et al. Journal article Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome (2023) Eckardt JN, Stasik S, Röllig C, Sauer T, Scholl S, Hochhaus A, Crysandt M, et al. Journal article Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies (2022) Cohen AD, Parekh S, Santomasso BD, Gallego Perez-Larraya J, Van De Donk NWCJ, Arnulf B, Mateos MV, et al. Journal article Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage (2021) Fernandez De Larrea C, Kyle R, Rosinol L, Paiva B, Engelhardt M, Usmani S, Caers J, et al. Journal article Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia (2021) Rautenberg C, Stoelzel F, Roellig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, et al. Journal article Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma (2021) Leich E, Schreder M, Pischimarov J, Stuhmer T, Steinbrunn T, Rudelius M, Bruennert D, et al. Journal article Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020) Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, et al. Journal article